Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression

Paclitaxel is a first-line drug for treating epithelial ovarian cancer (EOC). However, prognosis for patients with advanced stage cancer remains poor due to primary or acquired drug resistance. Therefore, overcoming chemoresistance is one of the greatest challenges in treating EOC. In this study, we...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Nakamura, Koji, Sawada, Kenjiro, Miyamoto, Mayuko, Kinose, Yasuto, Yoshimura, Akihiko, Ishida, Kyoso, Kobayashi, Masaki, Shimizu, Aasa, Nakatsuka, Erika, Hashimoto, Kae, Mabuchi, Seiji, Kimura, Tadashi
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2019
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6363016/
https://ncbi.nlm.nih.gov/pubmed/30774764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26586
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares